Up a level |
Neoptolemos, JP, Palmer, DH ORCID: 0000-0002-7147-5703, Ghaneh, P, Psarelli, EE ORCID: 0000-0002-3102-0288, Valle, JW, Halloran, CM ORCID: 0000-0002-5471-4178, Faluyi, O, O'Reilly, DA, Cunningham, D, Wadsley, J et al (show 24 more authors)
(2017)
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
Lancet (London, England), 389 (10073).
pp. 1011-1024.
Neoptolemos, JP, Palmer, DH ORCID: 0000-0002-7147-5703, Ghaneh, P, Psarelli, EE ORCID: 0000-0002-3102-0288, Valle, JW, Halloran, CM ORCID: 0000-0002-5471-4178, Faluyi, O, O'Reilly, DA, Cunningham, D, Wadsley, J et al (show 24 more authors)
(2017)
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
Lancet (London, England), 389 (10073).
1011 - 1024.
Pergolini, Ilaria, Schorn, Stephan, Goess, Rüdiger, Novotny, Alexander R, Ceyhan, Güralp O, Friess, Helmut, Demir, Ihsan Ekin, Adham, M, Allen, P, Andersson, R et al (show 23 more authors)
(2022)
Drain use in pancreatic surgery: Results from an international survey among experts in the field.
Surgery, 172 (1).
pp. 265-272.